In other studies that included patients with renal cell carcinoma or recurrent head and neck cancer treated with nivolumab, it was shown that expression of PD-L1 was a significant predictor of nivolumab efficacy.34 Here, CD274 is linked to hereditary clear cell renal cell carcinoma.